Lorazepam: uses, dosing, side effects & brands

Lorazepam is a benzodiazepine used to treat Anxiety Disorders, Catatonia, Depressive Disorder, Partial Epilepsies.

The FDA classifies lorazepam as a benzodiazepine. Benzodiazepines boost the brain's main calming chemical, GABA, by binding to the GABA-A receptor and making its chloride channel open more often. This quiets nerve activity, producing sedation, reduced anxiety, muscle relaxation, and protection against seizures. If you are checking whether it is safe to combine with something else, the class is what matters — two drugs from the same class usually should not be stacked.

The label warns against combining lorazepam with alcohol because of additive central-nervous-system depression, not a disulfiram-type reaction. Drug Interactions states that benzodiazepines, including lorazepam, produce increased CNS-depressant effects when given with alcohol (and other CNS depressants such as barbiturates, antipsychotics, sedatives, antidepressants, and narcotic analgesics). Patients are warned that their tolerance for alcohol and other CNS depressants will be diminished. The boxed warning notes that abuse/misuse commonly involving alcohol is associated with serious outcomes including respiratory depression, overdose, or death, and overdose combining benzodiazepines with alcohol may be fatal. The Medication Guide directs patients not to drink alcohol while taking lorazepam without first talking to their prescriber, because the combination can cause severe drowsiness, breathing problems (respiratory depression), coma, and death. This is what lorazepam's FDA label says; alcohol advice depends on your dose and health, so confirm with your pharmacist.

Yes, in the BOXED warning. Continued use of lorazepam may lead to clinically significant physical dependence, and the risks of dependence and withdrawal increase with longer treatment duration and higher daily dose. The label states that abrupt discontinuation or rapid dosage reduction after continued use may precipitate acute withdrawal reactions that can be life-threatening. To reduce this risk, the label directs the prescriber to use a gradual taper to discontinue lorazepam or reduce the dosage (per Dosage and Administration and Warnings). The label also describes a neonatal withdrawal syndrome with use late in pregnancy. Do not stop lorazepam on your own — any change is a prescriber-managed decision.

The elimination half-life of lorazepam is about 12 hours (mean) — that is how long the body takes to clear half of a dose. This is the half-life of lorazepam itself. Its main breakdown product (lorazepam glucuronide) lasts longer (about 18 hours) but is inactive, so it does not extend the drug's effect. The half-life can be longer in older adults and in people with liver or kidney problems. Half-life is not the same as how long a drug test can detect the drug, and it varies with age, kidney and liver function.

It depends on the medicine. We check it against the FDA labels rather than guessing: our interaction checker searches each drug's own label for the other and quotes what it says, naming the section it came from. Run lorazepam against whatever else you take — and remember that a label not naming a drug is not the same as that combination being safe.

We track 3 lorazepam-containing products in the U.S.: Lorazepam, Ativan and Loreev XR. They are the same active ingredient; they differ in form, manufacturer, price and FDA recall record.

Across the brands we track, lorazepam is currently marketed as injectable, solution, liquid, tablet and capsule, extended release, per the FDA's National Drug Code Directory. Each form is dosed differently — follow the label for the exact product you were prescribed.

Yes. Our catalog lists 1 generic lorazepam product alongside the brand versions. A generic has the same active ingredient and must meet the FDA's bioequivalence standard; it usually costs less. Ask your pharmacist which one your plan covers.

The FDA's Enforcement database lists at least 5 recall records whose product description mentions lorazepam. The most recent: Lorazepam Injection (Jul 22, 2025). A recall applies to specific lots, not to the drug as a whole — check the record for the affected lot numbers.

Alcohol: the FDA label says to avoid alcohol — see the alcohol section above for what it actually says. This is what the FDA label and our cited sources say — it is not a complete list. Your pharmacist can check your own combination.

In a sample of about 3,500 patients treated for anxiety, the most frequent side effects were sedation (15.9%), dizziness (6.9%), weakness (4.2%), and unsteadiness (3.4%). The label notes that sedation and unsteadiness both become more common with advancing age, which is why lorazepam is a fall and fracture risk in older adults. Because roughly one in six people is noticeably sedated, plan on not driving until you know how it affects you.

It covers three risks. One, taking lorazepam with opioids can cause profound sedation, respiratory depression, coma, and death — the combination should be used only when there is no adequate alternative, at the lowest dose and shortest duration, with monitoring. Two, lorazepam carries risk of abuse, misuse, and addiction that can lead to overdose or death; prescribers are told to assess that risk before starting and to keep monitoring, and patients should be counseled about safe use and storage. Three, continued use produces clinically significant physical dependence, and abruptly stopping or quickly cutting the dose can cause acute withdrawal reactions that can be life-threatening. The label is explicit that dependence and withdrawal risk grow with longer treatment and higher daily doses.

The label gives two contraindications: hypersensitivity to benzodiazepines or to any ingredient in the formulation, and acute narrow-angle glaucoma. Those are absolute 'do not use' situations. Separately — not a contraindication but a real risk — anyone taking an opioid, drinking alcohol, or using other CNS depressants faces the breathing-suppression danger described in the boxed warning, and lorazepam should be used with particular care in people with existing respiratory problems or sleep apnea and in older adults.

Faster than most people expect. The label states withdrawal symptoms, including rebound insomnia, can appear after stopping ordinary recommended doses taken for as little as one week. Reported withdrawal symptoms include headache, anxiety, tension, depression, insomnia, restlessness, confusion, irritability, and sweating; seizures are the serious end of the range and are more likely in people with a pre-existing seizure disorder. The label's instruction is to taper gradually rather than stop abruptly. If you have been taking lorazepam regularly, ask your prescriber for a taper plan — do not stop on your own.

Only when a prescriber has decided there is no adequate alternative, and then at the lowest dose for the shortest time with close monitoring. The combination can cause profound sedation, respiratory depression, coma, and death. That is the first item in the boxed warning. Alcohol and other sedating drugs — sleep aids, muscle relaxants, sedating antihistamines, other benzodiazepines — add to the same effect. Make sure every prescriber you see knows about both drugs, and make sure someone close to you knows the warning signs: extreme drowsiness, confusion, and slow or shallow breathing.

"In your system" means two different things. The first is how long the drug keeps acting and clears from your blood, which is tied to its elimination half-life. Lorazepam's half-life is about 14 hours (14±5 hours in clinical pharmacology references), and a drug is largely cleared after roughly 4-5 half-lives — so for most people lorazepam is substantially eliminated in about 2.5-3 days after the last dose. The second meaning is how long a drug test can still detect it, which is longer than clearance because tests pick up trace metabolites: lorazepam is broken down to lorazepam-glucuronide, which can be measured for days after the drug itself has stopped having an effect. These are approximate ranges from laboratory references, not guarantees; only a clinician or testing lab can interpret a specific result.

Urine is the most common test. In a controlled detection-window study, lorazepam remained positive in urine for up to about 144 hours (6 days) after exposure, and laboratory sources generally cite a urine window of roughly 2-6 days (sources vary by lab and cutoff). The exact time depends on dose, how long and how often it was used, your metabolism, hydration, and the specific assay's cutoff. An important, honest caveat: standard benzodiazepine immunoassay screens can MISS lorazepam. Most benzodiazepines appear in urine mainly as glucuronide conjugates, and common screens have very poor cross-reactivity to lorazepam-glucuronide (clonazepam's metabolite is similarly poorly detected), so a routine screen can read negative even when lorazepam is present — in one documented Mayo Clinic case a patient taking lorazepam daily as prescribed screened negative on the benzodiazepine immunoassay. By contrast, these same screens have relatively good cross-reactivity with alprazolam's metabolite (a-hydroxyalprazolam), so not all benzodiazepines are missed equally. Confirmatory testing (LC-MS/MS) or a benzodiazepine-specific panel is needed to reliably detect lorazepam. Ranges are approximate; only the testing lab can interpret your result.

Blood and saliva windows are shorter than urine because they track the parent drug more closely. Blood/plasma typically detects lorazepam from a few hours up to about 3 days depending on dose and timing. Saliva (oral fluid) is shorter still: in the cited detection-window study a single lorazepam dose was positive in oral fluid for only about 8 hours. Hair testing is unreliable for lorazepam specifically — unlike most other benzodiazepines, lorazepam was not detectable in hair in that same study, where researchers could not detect a single dose even using a very sensitive method (limit of quantitation 1 pg/mg). So while hair testing has a long window for many benzodiazepines, it should not be assumed to catch lorazepam. All figures are typical ranges from laboratory references and vary by individual and assay; a testing lab is the only authority on a specific sample.

Several factors shift the window. Dose and frequency matter most: a single dose clears faster than chronic daily use, which builds up tissue stores. Metabolism varies with age (older adults often clear it more slowly) and, to a lesser degree, liver and kidney function — though lorazepam is handled by direct glucuronidation rather than the CYP450 enzymes, so it is somewhat less affected by liver impairment than some other benzodiazepines. Body composition and hydration influence urine concentration and can move a result above or below a cutoff. Finally, the test itself is decisive: the specimen type (urine, blood, saliva, hair), the assay, and the cutoff threshold all change what is detectable — and standard benzodiazepine screens may not flag lorazepam at all without confirmatory testing. These are approximate ranges from laboratory references, not guarantees, and only a clinician or testing lab can interpret a specific result.